WO2002074250A3 - Methods and reagents for decreasing clinical reaction to allergy - Google Patents

Methods and reagents for decreasing clinical reaction to allergy Download PDF

Info

Publication number
WO2002074250A3
WO2002074250A3 PCT/US2002/009108 US0209108W WO02074250A3 WO 2002074250 A3 WO2002074250 A3 WO 2002074250A3 US 0209108 W US0209108 W US 0209108W WO 02074250 A3 WO02074250 A3 WO 02074250A3
Authority
WO
WIPO (PCT)
Prior art keywords
ige
modified
allergens
binding sites
disulfide bonds
Prior art date
Application number
PCT/US2002/009108
Other languages
French (fr)
Other versions
WO2002074250A2 (en
Inventor
Michael Caplan
Howard Sosin
Hugh Sampson
Gary A. Bannon
Wesley A. Burks
Gael Cockrell
Cesar M. Compadre
Cathie Connaughton
Ricki M. Helm
Nina E. King
Randall A. Kopper
Sohelia J. Maleki
Patrick A. Rabjohn
David S. Shin
J. Steven Stanley
Original Assignee
Panacea Pharmaceuticals
Mount Sinai School Of Medicine Of New York University
University Of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals, Mount Sinai School Of Medicine Of New York University, University Of Arkansas filed Critical Panacea Pharmaceuticals
Priority to AU2002306850A priority Critical patent/AU2002306850A1/en
Publication of WO2002074250A2 publication Critical patent/WO2002074250A2/en
Publication of WO2002074250A3 publication Critical patent/WO2002074250A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Abstract

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.
PCT/US2002/009108 2001-03-16 2002-03-18 Methods and reagents for decreasing clinical reaction to allergy WO2002074250A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002306850A AU2002306850A1 (en) 2001-03-16 2002-03-18 Methods and reagents for decreasing clinical reaction to allergy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27682201P 2001-03-16 2001-03-16
US60/276,822 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002074250A2 WO2002074250A2 (en) 2002-09-26
WO2002074250A3 true WO2002074250A3 (en) 2003-10-09

Family

ID=23058195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009108 WO2002074250A2 (en) 2001-03-16 2002-03-18 Methods and reagents for decreasing clinical reaction to allergy

Country Status (2)

Country Link
AU (1) AU2002306850A1 (en)
WO (1) WO2002074250A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
EP1547610A1 (en) * 2003-12-23 2005-06-29 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Immunotherapy for food allergy by reduced and alkylated food allergens
CA2708406A1 (en) * 2008-01-08 2009-07-16 Alk-Abello A/S Allergy vaccine composition for mucosal administration
EP2110383A1 (en) * 2008-04-14 2009-10-21 Biomay AG Hypoallergenic variants
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
EP2861240B1 (en) 2012-06-15 2020-09-09 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CA3177836A1 (en) 2012-10-30 2014-05-08 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
JP7007534B2 (en) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド New immunotherapeutic composition and its use
EP3141258A1 (en) * 2015-09-08 2017-03-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Soybean allergy related epitopes
CN111955648B (en) * 2020-08-13 2021-07-02 江南大学 Method for detecting soybean globulin sensitization peptide fragment and eliminating soybean globulin sensitization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038978A1 (en) * 1998-01-31 1999-08-05 University Of Arkansas Methods and reagents for decreasing allergic reactions
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038978A1 (en) * 1998-01-31 1999-08-05 University Of Arkansas Methods and reagents for decreasing allergic reactions
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURKS A.W. ET AL.: "Mapping and mutational analysis of the IgE-binding epitopes on Ara h1, a legume vicilin protein and a major allergen in peanut hypersensitivity", EUR. J. BIOCHEM., vol. 245, April 1997 (1997-04-01), pages 334 - 339, XP002107203 *
DEL VAL G. ET AL.: "Thioredoxtin treatment increases digestibility and lowers allergenicity of milk", J. ALLERGY CLIN. IMMUNOL., vol. 103, no. 4, April 1999 (1999-04-01), pages 690 - 697, XP002964234 *
HOYNE G.F. ET AL.: "Peptide-mediated regulation of the allergic. Immune response", IMMUNOL. CELL BIOL., vol. 74, no. 2, April 1996 (1996-04-01), pages 180 - 186, XP002964235 *
STANLEY S.J. ET AL.: "Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen ara h2", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 342, no. 2, June 1997 (1997-06-01), pages 244 - 253, XP000946317 *
VAILES L.D. ET AL.: "Fine specificity of B-cell epitopes on felis domesticus allergen I (fel d I): effect of reduction and alkylation or deglycosylation on Fel d I structure and antibody binding", J. ALLERGY CLIN. IMMUNOL., vol. 93, no. 1 PART 1, January 1994 (1994-01-01), pages 22 - 33, XP002964236 *

Also Published As

Publication number Publication date
AU2002306850A1 (en) 2002-10-03
WO2002074250A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DE69940805D1 (en) METHOD AND REAGENTS FOR REDUCING THE CLINICAL REACTION TO ALLERGY
WO2002074250A3 (en) Methods and reagents for decreasing clinical reaction to allergy
WO2003018771A3 (en) A system for antibody expression and assembly
HK1074991A1 (en) Cd16a binding proteins and use for the treatment of immune disorders cd16a
WO2005047326A3 (en) Interleukin-10 antibodies
WO2003048327A3 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
WO2004067568A3 (en) Human il-1 beta antagonists
EP2204189A3 (en) Allergen peptide fragments and use thereof
EP1421539A4 (en) Stabilized proteins with engineered disulfide bonds
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2005011730A8 (en) Microsome vaccine
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO2003072746A3 (en) Subtilisin carlsberg proteins with reduced immunogenicity
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2002012899A3 (en) Peptides presented by cells
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2000052154A3 (en) Methods and reagents for decreasing clinical reaction to allergy
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
EP2292638A3 (en) MAGE-C2 antigenic peptides and uses thereof
WO2004018619A3 (en) P53 binding t cell receptor molecules and uses thereof
WO2003100022A3 (en) Methods and dna constructs for high yield production of polypeptides
WO2003042656A3 (en) Identifying and reducing the allergenicity of food proteins
WO2004096156A3 (en) Toll-like receptor 9 effector agents and uses thereof
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP